Picture of Lucid Diagnostics logo

LUCD Lucid Diagnostics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapSucker Stock

Lucid Diagnostics Inc expected to post a loss of 12 cents a share - Earnings Preview

Lucid Diagnostics Inc LUCD.OQ LUCD.O is expected to  show a rise in quarterly revenue when it reports  results on August 13 for the period ending June 30 2025

The New York City-based  company is expected to report a 17.0% increase in revenue to $1.142 million from $976 thousand a year ago, according to the mean estimate from 6 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Lucid Diagnostics Inc is for a loss of 12 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Lucid Diagnostics Inc is $3.00, about 66.8% above its last closing price of $1.00

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDINGSTARMINESMARTESTIMATE®LSEG IBES ESTIMATEACTUALBEAT, MET, MISSEDSURPRISE %
Mar. 31 2025-0.16-0.16-0.52Missed-228.7
Dec. 31 2025-0.19-0.18Beat5.3
Sep. 30 2024-0.22-0.22-0.25Missed-13.6​
Jun. 30 2024-0.22-0.22-0.23Missed-4.5
​​Mar. 31 2024-0.26-0.27-0.40Missed-49.3
Dec. 31 2023-0.27-0.26-0.25Beat3​
Sep. 30 2023-0.27-0.27-0.34Missed-24.8
Jun. 30 2023-0.32-0.32-0.23Beat28.3
This summary was machine generated August 11 at 13:17 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Lucid Diagnostics

See all news